Now showing items 1-20 of 77

    • AKT Inhibition in Solid Tumors With AKT1 Mutations. 

      Hyman, DM; Smyth, LM; Donoghue, MTA; Westin, SN; Bedard, PL; Dean, EJ; Bando, H; El-Khoueiry, AB; Pérez-Fidalgo, JA; Mita, A; Schellens, JHM; Chang, MT; Reichel, JB; Bouvier, N; Selcuklu, SD; Soumerai, TE; Torrisi, J; Erinjeri, JP; Ambrose, H; Barrett, JC; Dougherty, B; Foxley, A; Lindemann, JPO; McEwen, R; Pass, M; Schiavon, G; Berger, MF; Chandarlapaty, S; Solit, DB; Banerji, U; Baselga, J; Taylor, BS (2017-07)
      Purpose AKT1 E17K mutations are oncogenic and occur in many cancers at a low prevalence. We performed a multihistology basket study of AZD5363, an ATP-competitive pan-AKT kinase inhibitor, to determine the preliminary ...
    • Antibody-drug conjugates--an emerging class of cancer treatment. 

      Diamantis, N; Banerji, U (2016-02)
      Antibody-drug conjugates (ADCs) are an emerging novel class of anticancer treatment agents that combines the selectivity of targeted treatment with the cytotoxic potency of chemotherapy drugs. New linker technology associated ...
    • Application of Liquid Biopsies in Cancer Targeted Therapy. 

      Sumanasuriya, S; Lambros, MB; de Bono, JS (2017-11)
      As a growing body of evidence demonstrates intertumoral and intratumoral heterogeneity and clonal evolution, both during carcinogenesis and also throughout treatment resulting in acquired drug resistance, the utility of ...
    • The Association of Cancer Physicians responds to "Cancer drugs, survival, and ethics". 

      Dangoor, A; Joffe, J; Januszewski, A; Mansi, J; Cunningham, D; Selby, P; 17 other authors and members of the Association of Cancer Physicians, UK (2016-12-05)
    • Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development? 

      Carden, CP; Sarker, D; Postel-Vinay, S; Yap, TA; Attard, G; Banerji, U; Garrett, MD; Thomas, GV; Workman, P; Kaye, SB; de Bono, JS (2010-02)
      Anticancer drug development remains slow, costly and inefficient. One way of addressing this might be the use of predictive biomarkers to select patients for Phase I/II trials. Such biomarkers, which predict response to ...
    • CDK4/6 Inhibitors: Promising Opportunities beyond Breast Cancer. 

      Lim, JSJ; Turner, NC; Yap, TA (2016-07)
      Patnaik and colleagues report on the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of abemaciclib for the treatment of advanced solid cancers, demonstrating antitumor activity in advanced breast ...
    • Chemotherapy with radiotherapy influences time-to-development of radiation-induced sarcomas: a multicenter study. 

      Zhang, AY; Judson, I; Benson, C; Wunder, JS; Ray-Coquard, I; Grimer, RJ; Quek, R; Wong, E; Miah, AB; Ferguson, PC; Dufresne, A; Teh, JYH; Stockler, M; Tattersall, MHN (2017-07)
      An increasing number and proportion of cancer patients with apparently localised disease are treated with chemotherapy and radiation therapy in contemporary oncology practice. In a pilot study of radiation-induced sarcoma ...
    • Circulating tumor DNA-From bench to bedside. 

      Lim, JSJ; Janku, F; Yap, TA (2017-05)
      In the era of personalized medicine, tumor sampling is paramount to enable the assessment of actionable molecular aberrations to help rationalize and guide treatment decisions. Longitudinal tracking of such aberrations may ...
    • Clinical development of new drug-radiotherapy combinations. 

      Sharma, RA; Plummer, R; Stock, JK; Greenhalgh, TA; Ataman, O; Kelly, S; Clay, R; Adams, RA; Baird, RD; Billingham, L; Brown, SR; Buckland, S; Bulbeck, H; Chalmers, AJ; Clack, G; Cranston, AN; Damstrup, L; Ferraldeschi, R; Forster, MD; Golec, J; Hagan, RM; Hall, E; Hanauske, A-R; Harrington, KJ; Haswell, T; Hawkins, MA; Illidge, T; Jones, H; Kennedy, AS; McDonald, F; Melcher, T; O'Connor, JPB; Pollard, JR; Saunders, MP; Sebag-Montefiore, D; Smitt, M; Staffurth, J; Stratford, IJ; Wedge, SR; NCRI CTRad Academia-Pharma Joint Working Group (2016-10)
      In countries with the best cancer outcomes, approximately 60% of patients receive radiotherapy as part of their treatment, which is one of the most cost-effective cancer treatments. Notably, around 40% of cancer cures ...
    • Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trials. 

      Sundar, R; McVeigh, T; Dolling, D; Petruckevitch, A; Diamantis, N; Ang, JE; Chenard-Poiriér, M; Collins, D; Lim, J; Ameratunga, M; Khan, K; Kaye, SB; Banerji, U; Lopez, J; George, AJ; de Bono, JS; van der Graaf, WT (2018-09)
      BACKGROUND:Adolescent and young adult (AYA) patients with advanced solid tumours are often considered for phase I clinical trials with novel agents. The outcome of AYAs in these trials have not been described before. AIM:To ...
    • COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss. 

      Crabb, SJ; Martin, K; Abab, J; Ratcliffe, I; Thornton, R; Lineton, B; Ellis, M; Moody, R; Stanton, L; Galanopoulou, A; Maishman, T; Geldart, T; Bayne, M; Davies, J; Lamb, C; Popat, S; Joffe, JK; Nutting, C; Chester, J; Hartley, A; Thomas, G; Ottensmeier, C; Huddart, R; King, E (2017-12)
      BACKGROUND:Cisplatin is one of the most ototoxic chemotherapy drugs, resulting in a permanent and irreversible hearing loss in up to 50% of patients. Cisplatin and gentamicin are thought to damage hearing through a common ...
    • Combinatorial drug therapy for cancer in the post-genomic era. 

      Al-Lazikani, B; Banerji, U; Workman, P (2012-07-10)
      Over the past decade, whole genome sequencing and other 'omics' technologies have defined pathogenic driver mutations to which tumor cells are addicted. Such addictions, synthetic lethalities and other tumor vulnerabilities ...
    • Combine and conquer: challenges for targeted therapy combinations in early phase trials. 

      Lopez, JS; Banerji, U (2017-01)
      Our increasing understanding of cancer biology has led to the development of molecularly targeted anticancer drugs. The full potential of these agents has not, however, been realised, owing to the presence of de novo ...
    • Combining Molecularly Targeted Agents: Is More Always Better? 

      Sundar, R; Valeri, N; Harrington, KJ; Yap, TA (2017-03)
      The concurrent targeting of critical nodes along key signaling pathways with molecularly targeted agents is a rational antitumor strategy, which has had varying degrees of success. Combinatorial challenges include overcoming ...
    • Complications of hyperglycaemia with PI3K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials. 

      Geuna, E; Roda, D; Rafii, S; Jimenez, B; Capelan, M; Rihawi, K; Montemurro, F; Yap, TA; Kaye, SB; De Bono, JS; Molife, LR; Banerji, U (2015-12)
      BACKGROUND:PI3K-AKT-mTOR inhibitors (PAMi) are promising anticancer treatments. Hyperglycaemia is a mechanism-based toxicity of these agents and is becoming increasingly important with their use in larger numbers of patients. ...
    • Conducting non-commercial international clinical trials: the ICR-CTSU experience. 

      Fox, L; Toms, C; Kernaghan, S; Snowdon, C; Bliss, JM (2017-09-26)
      BACKGROUND:Academic clinical trials play a fundamental role in the development of new treatments, the repurposing of existing treatments and in addressing areas of unmet clinical need. With cancer treatments increasingly ...
    • CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions. 

      Zimmermann, M; Murina, O; Reijns, MAM; Agathanggelou, A; Challis, R; Tarnauskaitė, Ž; Muir, M; Fluteau, A; Aregger, M; McEwan, A; Yuan, W; Clarke, M; Lambros, MB; Paneesha, S; Moss, P; Chandrashekhar, M; Angers, S; Moffat, J; Brunton, VG; Hart, T; de Bono, J; Stankovic, T; Jackson, AP; Durocher, D (2018-07-04)
      The observation that BRCA1- and BRCA2-deficient cells are sensitive to inhibitors of poly(ADP-ribose) polymerase (PARP) has spurred the development of cancer therapies that use these inhibitors to target deficiencies in ...
    • Critical parameters in targeted drug development: the pharmacological audit trail. 

      Banerji, U; Workman, P (2016-08)
      The Pharmacological Audit Trail (PhAT) comprises a set of critical questions that need to be asked during discovery and development of an anticancer drug. Key aspects include: (1) defining a patient population; (2) ...
    • Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers. 

      Stewart, A; Coker, EA; Pölsterl, S; Georgiou, A; Minchom, AR; Carreira, S; Cunningham, D; O'Brien, ME; Raynaud, FI; de Bono, JS; Al-Lazikani, B; Banerji, U (2019-08)
      It is increasingly appreciated that drug response to different cancers driven by the same oncogene is different and may relate to differences in rewiring of signal transduction. We aimed to study differences in dynamic ...
    • Does age matter? A comparison of health-related quality of life issues of adolescents and young adults with cancer. 

      Sodergren, SC; Husson, O; Rohde, GE; Tomaszewska, IM; Griffiths, H; Pessing, A; Yarom, N; Hooker, L; Din, A; Darlington, AS; EORTC Quality of Life Group (2018-11)
      OBJECTIVE:Health-related quality of life (HRQoL) concerns of adolescents and young adults (AYAs) aged 14-25 years were compared with those of older adults (26-60 years) with cancer. METHODS:AYAs and older adults receiving ...